The buccal administration of a Cannabis sativa L./Cannabis indica L. extract as an adjunct to opioid analgesia for the management of intractable pain in patients diagnosed with advanced cancer: a safety, tolerability and exploratory end-point pilot study
NanaBisTM is an investigative new product containing 1:1 ratio of Cannabidiol (CBD) and delta-9-trethydrocannabinol (THC), in a sub-micron spray applied to the oro-buccal membrane.
16 June 2017
Northern Sydney Local Health District
Royal North Shore Hospital, Oncology Department